[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Citations 0
From the Food and Drug Administration
November 6, 2002

Adjuvant Breast Cancer Treatment

Author Affiliations

Not Available

Not Available

JAMA. 2002;288(17):2112. doi:10.1001/jama.288.17.2112-JFD20011-2-1

The FDA has approved anastrozole (Arimidex, AstraZeneca Pharmaceuticals LP, Wilmington, Del) for adjuvant treatment of postmenopausal women with hormone receptor–positive early breast cancer. The drug, a nonsteroidal aromatase inhibitor, had been approved for two indications in postmenopausal women, including first-line treatment of locally advanced or metastatic breast cancer and treatment of advanced breast cancer in women with disease progression following tamoxifen therapy.

First Page Preview View Large
First page PDF preview
First page PDF preview